5-nitro-benzo[b]thiophene-3-carboxylic acid amide | 1058740-14-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并噻吩类
• 英文名称: 5-nitro-benzo[b]thiophene-3-carboxylic acid amide
• 英文别名: 5-Nitro-3-benzothiophencarboxylic acid amide；5-nitro-1-benzothiophene-3-carboxamide
• CAS: 1058740-14-9
• 化学式: C₉H₆N₂O₃S
• 分子量: 222.224
• InChiKey: JKXGSCKJEXJKQT-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.6
• 重原子数：
  15
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  117
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  6-nitro-benzo[b]thiophene-3-carboxylic acid 、 5-nitro-benzo[b]thiophene-3-carboxylic acid 、 在 crude product 、 silica gel 作用下， 生成 5-nitro-benzo[b]thiophene-3-carboxylic acid amide
  参考文献：
  名称：

  SUBSTITUTED ARYLSULPHONYLGLYCINES, THE PREPARATION THEREOF AND THE USE THEREOF AS PHARMACEUTICAL COMPOSITIONS

  摘要：

  本发明涉及一般式（I）的取代芳基磺酰甘氨酸，其中R、X、Y和Z如权利要求1中所定义，其互变异构体、对映异构体、二对映异构体、混合物及其盐具有有价值的药理学性质，尤其是抑制糖原磷酸化酶a与糖原相关蛋白磷酸酶1（PP1）的GL亚单位的相互作用，并可用作制药组合物。

  公开号：

  US20100130557A1

文献信息

• 4-Aryl-1-(indanmethyl dihydrobenzofuranmethyl or dihydrobenzothiophenemethyl) piperidines tetrahydropyridines or piperazines
  申请人：——

  公开号：US20030195356A1

  公开（公告）日：2003-10-16

  4-Aryl- 1 -(indanmethyl, dibydrobenzofuramethyl or dihydrobenzotbiophenemethyl) piperidine, -tetrabydropyridine or -piperazine compounds of general formula (I) 1 wherein one of X and Y is CH 2 , and the other one is CH 2 , O or S; Z is N, C, CH or COH; Ar is an optionally substituted aryl group; R 1 is hydrogen, alkyl, cycloalkyl, cycloakylalkyl, aryl, arylalkyl, acyl, thioacyl, alkylsulfonyl, trifloromethylsulfonyl, arylsulfonyl, a group R 9 VCO— where V is O or S and R 9 is alkyl or aryl, or a group R 10 R 11 NCO or R 10 R 11 NCS— wherein R 10 and R 11 are hydrogen, alkyl or aryl, or R 10 and R 11 are linked to form a ring R 2 is hydrogen, alkyl, cycloalkyl or cycloalkylalkyl; or R 1 and R 2 are linked to form a ring; R 3 —R 5 are hydrogen, halogen, alkyl, alkylcarbonyl, phenylcarbonyl, alkoxy, alkylthio, hydroxy, alkylsulfonyl, cyano, trifluoromethyl, cycloalkyl, cycloalkylaLkyl or nitro; R 6 and R 7 are bydrogen or alkyl or they are linked to constitute a 3-7-membered ring; R 8 is hydrogen or alkyl; have effects at central serotonergic receptors and are therefore useful in the treatment of certain psychic and neurologic disorders.

  通式（I）的4-芳基-1-(茚达甲基、二氢苯并呋喃甲基或二氢苯并二苯甲基)-哌啶、四氢吡啶或哌嗪化合物，其中X和Y中的一个是CH2，另一个是 、O或S；Z是N、C、CH或COH；Ar是可选取代的芳基基团；R1是氢、烷基、环烷基、环烷基烷基、芳基、芳基烷基、酰基、硫酰基、烷基磺酰基、三氟甲基磺酰基、芳基磺酰基、R9VCO—其中V为O或S且R9为烷基或芳基，或R10R11NCO或R10R11NCS—其中R10和R11为氢、烷基或芳基，或R10和R11连接形成环；R2是氢、烷基、环烷基或环烷基烷基；或R1和R2连接形成环；R3-R5是氢、卤素、烷基、烷基羰基、苯基羰基、烷氧基、烷基硫基、羟基、烷基磺酰基、氰基、三氟甲基、环烷基、环烷基烷基或硝基；R6和R7是氢或烷基，或它们连接构成3-7成员环；R8是氢或烷基；在中枢5-羟色胺受体上具有作用，因此在治疗某些精神和神经疾病方面有用。
• 4-Aryl-1-(indanmethyl, dihydrobenzofuranmethyl or dihydrobenzothiophene-methyl) piperazines
  申请人：H. Lundbeck A/S

  公开号：US06218394B1

  公开（公告）日：2001-04-17

  4-Aryl-1-(indanmethyl, dihydrobenzofuramethyl or dihydrobenzothiophenemethyl) piperidine, -tetrahydropyridine or -piperazine compounds of general formula (I) wherein one of X and Y is CH2, and the other one is CH2, O or S; Z is N, C, CH or COH; Ar is an optionally substituted aryl group; R1 is hydrogen, alkyl, cycloalkyl, cycloalkylalkyl, aryl, arylalkyl, acyl, thioacyl, alkylsulfonyl, trifluoromethylsulfonyl, arylsulfonyl, a group R9VCO— where V is O or S and R9 is alkyl or aryl, or a group R10R11NCO— or R10R11NCS— wherein R10 and R11 are hydrogen, alkyl or aryl, or R10 and R11 are linked to form a ring; R2 is hydrogen, alkyl, cycloalkyl or cycloalkylalkyl; or R1 and R2 are linked to form a ring; R3-R5 are hydrogen, halogen, alkyl, alkylcarbonyl, phenylcarbonyl, alkoxy, alkylthio, hydroxy, alkylsulfonyl, cyano, trifluoromethyl, cycloalkyl, cycloalkylalkyl or nitro; R6 and R7 are hydrogen or alkyl or they are linked to constitute a 3-7-membered ring; R8 is hydrogen or alkyl; have effects at central serotonergic receptors and are therefore useful in the treatment of certain psychic and neurologic disorders.

  通式（I）中，其中X和Y中的一个是CH2，另一个是 ，O或S; Z是N，C，CH或COH; Ar是一个可选择取代的芳基基团; R1是氢，烷基，环烷基，环烷基烷基，芳基，芳基烷基，酰基，硫酰基，烷基磺酰基，三氟甲基磺酰基，芳基磺酰基，一个R9VCO-基团，其中V是O或S，R9是烷基或芳基，或一个R10R11NCO-或R10R11NCS-基团，其中R10和R11是氢，烷基或芳基，或R10和R11连接形成一个环; R2是氢，烷基，环烷基或环烷基烷基; 或者R1和R2连接形成一个环; R3-R5是氢，卤素，烷基，烷基羰基，苯基羰基，烷氧基，烷基硫基，羟基，烷基磺酰基，氰基，三氟甲基，环烷基，环烷基烷基或硝基; R6和R7是氢或烷基，或它们连接形成一个3-7成员环; R8是氢或烷基; 这些化合物在中枢5-羟色胺受体上产生作用，因此在某些精神和神经疾病的治疗中有用。
• 4-aryl-1-(indanmethyl dihydrobenzofuranmethyl or dihydrobenzothiophenemethyl) piperidines tetrahydropyridines or piperazines
  申请人：H. Lundbeck A/S

  公开号：US06767907B2

  公开（公告）日：2004-07-27

  4-Aryl-1-(indanmethyl, dihydrobenzofuranmethyl or dihydrobenzothiophenemethyl)piperidine, -tetrahydropyridine or -piperazine compounds of general formula (I), wherein one of X and Y is CH2 and the other one is CH2, O or S; Z is N, C, CH or COH; Ar is an optionally substituted aryl group; R1 is hydrogen, alkyl, cycloalkyl, cycloalkylalkyl, aryl, arylalkyl, acyl, thioacyl, alkylsulfonyl, trifluoromethylsulfonyl, arylsulfonyl, a group R9VCO— where V is O or S and R9 is alkyl or aryl, or a group R10R11NCO— or R10R11NCS— wherein R10 and R11 are hydrogen, alkyl or aryl, or R10 and R11 are linked to form a ring; R2 is hydrogen, alkyl, cykcloalkyl or cycloalkylalkyl; or R1 and R2 are linked to form a ring; R3-R5 are hydrogen, halogen, alkyl, alkylcarbonyl, phenylcarbonyl, alkoxy, alkylthio, hydroxy, alkylsulfonyl, cyano, trifluoromethyl, cycloalkyl, cycloalkylalkyl or nitro; R6 and R7 are hydrogen or alkyl or they are linked to constitute 3-7 membered ring; R8 is hydrogen or alkyl; have effects at central serotonergic receptors and are therefore useful in the treatment of certain psychic and neurologic disorders.

  通式（I）的4-Aryl-1-(indanmethyl、dihydrobenzofuranmethyl或dihydrobenzothiophenemethyl)piperidine、-tetrahydropyridine或-piperazine化合物，其中X和Y中的一个为CH2，另一个为 、O或S；Z为N、C、CH或COH；Ar为可选取代的芳基基团；R1为氢、烷基、环烷基、环烷基烷基、芳基、芳基烷基、酰基、硫酰基、烷基磺酰基、三氟甲基磺酰基、芳基磺酰基、R9VCO—（其中V为O或S，R9为烷基或芳基）或R10R11NCO—或R10R11NCS—（其中R10和R11为氢、烷基或芳基，或R10和R11连接形成环）；R2为氢、烷基、环烷基或环烷基烷基；或R1和R2连接形成环；R3-R5为氢、卤素、烷基、烷基羰基、苯基羰基、烷氧基、烷基硫基、羟基、烷基磺酰基、氰基、三氟甲基、环烷基、环烷基烷基或硝基；R6和R7为氢或烷基或它们连接形成3-7成员环；R8为氢或烷基；在中枢5-羟色胺能受体上有作用，因此对某些精神和神经疾病的治疗有用。
• 4-aryl-1-(indanmethyl, dihydrobenzofuranmethyl or dihydrobenzothiophenemethyl) tetrahydropyridines or piperazines
  申请人：H. Lundbeck A/S

  公开号：US06743808B1

  公开（公告）日：2004-06-01

  4-Aryl-1-(indanmethyl, dihydrobenzofuranmethyl or dihydrobenzothiophenemethyl)piperidine, -tetrahydropyridine or -piperazine compounds of general formula (I), wherein one of X and Y is CH2 and the other one is CH2, O or S; Z is N, C, CH or COH; Ar is an optionally substituted aryl group; R1 is hydrogen, alkyl, cycloalkyl, cycloalkylalkyl, aryl, arylalkyl, acyl, thioacyl, alkylsulfonyl, trifluoromethylsulfonyl, arylsulfonyl, a group R9VCO— where V is O or S and R9 is alkyl or aryl, or a group R10R11NCO— or R10R11NCS— wherein R10 and R11 are hydrogen, alkyl or aryl, or R10 and R11 are linked to form a ring; R2 is hydrogen, alkyl, cycloalkyl or cycloalkylalkyl or R1 and R2 are linked to form a ring; R3-R5 are hydrogen, halogen, alkyl, alkylcarbonyl, phenylcarbonyl, alkoxy, alkylthio, hydroxy, alkylsulfonyl, cyano, trifluoromethyl, cycloalkyl, cycloalkylalkyl or nitro; R6 and R7 are hydrogen or alkyl or they are linked to constitute 3-7-membered ring; R8 is hydrogen or alkyl; have effects at central serotonergic receptors and are therefore useful in the treatment of certain psychic and neurologic disorders.

  通式（I）的4-芳基-1-(茚达甲基、二氢苯并呋喃甲基或二氢苯并噻吩甲基)哌啶、四氢吡啶或哌嗪化合物，其中X和Y中的一个是CH2，另一个是 、O或S；Z是N、C、CH或COH；Ar是一个可选择性取代的芳基基团；R1是氢、烷基、环烷基、环烷基烷基、芳基、芳基烷基、酰基、硫酰基、烷基磺酰基、三氟甲基磺酰基、芳基磺酰基、一个R9VCO—团，其中V是O或S，R9是烷基或芳基，或一个R10R11NCO—或R10R11NCS—团，其中R10和R11是氢、烷基或芳基，或R10和R11连接形成一个环；R2是氢、烷基、环烷基或环烷基烷基，或R1和R2连接形成一个环；R3-R5是氢、卤素、烷基、烷基羰基、苯基羰基、烷氧基、烷基硫基、羟基、烷基磺酰基、氰基、三氟甲基、环烷基、环烷基烷基或硝基；R6和R7是氢或烷基，或它们连接成3-7成员环；R8是氢或烷基；在中枢5-羟色胺受体上具有作用，因此在治疗某些精神和神经疾病方面有用。
• Substituted arylsulphonylglycines, the preparation thereof and the use thereof as pharmaceutical compositions
  申请人：Boehringer Ingelheim International GmbH

  公开号：US08232312B2

  公开（公告）日：2012-07-31

  The present invention relates to substituted arylsulphonylglycines of general formula (I) wherein R, X, Y and Z are defined as in claim 1, the tautomers, enantiomers, diastereomers, mixtures thereof and salts thereof, which have valuable pharmacological properties, particularly the suppression of the interaction of glycogen phosphorylase a with the GL subunit of glycogen-associated protein phosphatase 1 (PP1), and their use as pharmaceutical compositions.

  本发明涉及一般式（I）中定义为声明1中的R，X，Y和Z的取代芳基磺酰基甘氨酸，其互变异构体，对映异构体，顺反异构体，其混合物和盐，具有有价值的药理学特性，特别是抑制糖原磷酸化酶a与糖原相关蛋白磷酸酶1（PP1）的GL亚基的相互作用，并将其用作药物组成物。